Blueprint Medicines Corp Collaborations with Sixth Street and Royalty Pharma - Corporate Call Transcript
Good morning. My name is Daisy, and I'll be your conference coordinator today. At this time, I would like to welcome everyone to the Blueprint Medicines Conference Call. (Operator Instructions)
I would now like to hand over to Jenna Cohen to begin. Jenna, please go ahead.
Thank you, Daisy. Good morning, everyone, and welcome to the call. This morning we issued a press release highlighting Blueprint's $1.25 billion transformative, strategic, and nondilutive financing collaboration with Sixth Street and Royalty Pharma. You can access the press release as well as the slides that we'll be reviewing today by going to the Investors section of our website at www.blueprintmedicines.com.
Joining me on today's call are Kate Haviland, our Chief Executive Officer, who will discuss the importance of this deal for Blueprint Medicines; and Mike Landsittel, our Chief Financial Officer, who will review
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |